Motor signs during the course of Alzheimer disease

Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center, and Department of Neurology, New York, NY 10032, USA.
Neurology (Impact Factor: 8.3). 10/2004; 63(6):975-82. DOI: 10.1212/01.WNL.0000138440.39918.0C
Source: PubMed

ABSTRACT Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care.
To describe the progression and identify predictors of individual MOSIs in AD.
A cohort of 474 patients with AD at early stages was followed semiannually for up to 13.1 years (mean 3.6 years) in five centers in Europe and the United States. MOSIs were rated using a standardized portion of the Unified Parkinson's Disease Rating Scale. Overall, 3,030 visits/assessments of MOSIs (average 6.4/patient) were performed. Prevalence and incidence rates were calculated, and cumulative risk graphs were plotted for individual non-drug-induced MOSI domains. Rates of change over time taking into account potential covariates were also estimated. With use of each MOSI domain as outcome in Cox models, predictors of MOSI incidence were identified.
At least one MOSI was detected in 13% of patients at first examination and in 36% for the last evaluation. Total MOSI score increased at an annual rate of 3% of total possible score. Rates of annual change for speech/facial expression (4%), rigidity (2.45%), posture/gait (3.9%), and bradykinesia (3.75%) were of similar magnitude, and their occurrence increased from first (3 to 6%) to last (22 to 29%) evaluation. Tremor was less frequent throughout the course of the disease (4% at first and 7% at last evaluation) and worsened less (0.75% increase/year).
Most motor signs occur frequently and progress rapidly in Alzheimer disease. Tremor is an exception in that it occurs less frequently and advances at slower rates.

Download full-text


Available from: Jason Brandt, Jan 08, 2014
  • Source
    • "The general physical and neurological exam may often remain normal throughout most of the course of AD. Extrapyramidal signs (e.g., bradykinesia, rigidity, and reduced facial expression ) are seen in 30% of cases; however, rest tremor is rare (Scarmeas et al. 2004). Gait disturbances become more prominent with disease progression and are associated with a substantially higher risk for falls. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer disease (AD) is the most common cause of dementia in the elderly. Clinicopathological studies support the presence of a long preclinical phase of the disease, with the initial deposition of AD pathology estimated to begin approximately 10-15 years prior to the onset of clinical symptoms. The hallmark clinical phenotype of AD is a gradual and progressive decline in two or more cognitive domains, most commonly involving episodic memory and executive functions, that is sufficient to cause social or occupational impairment. Current diagnostic criteria can accurately identify AD in the majority of cases. As disease-modifying therapies are being developed, there is growing interest in the identification of individuals in the earliest symptomatic, as well as presymptomatic, stages of disease, because it is in this population that such therapies may have the greatest chance of success. The use of informant-based methods to establish cognitive and functional decline of an individual from previously attained levels of performance best allows for the identification of individuals in the very mildest stages of cognitive impairment.
    Cold Spring Harbor Perspectives in Medicine 05/2012; 2(5):a006148. DOI:10.1101/cshperspect.a006148 · 7.56 Impact Factor
  • Source
    • "The study was approved by each local institutional review board. The inclusion and exclusion criteria are fully described elsewhere (Richards et al., 1993; Stern et al., 1993; Scarmeas et al., 2004). Briefly, subjects met DSM-III-R criteria for primary degenerative dementia of the Alzheimer type and NINDS-ADRDA criteria for probable AD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To (1) compare home health and informal (unpaid) services utilization among patients with Alzheimer's disease (AD), (2) examine longitudinal changes in services use, and (3) estimate possible interdependence of home health and informal care utilization. The sample is drawn from the Predictors Study, a large, multicenter cohort of patients with probable AD, prospectively followed annually for up to 7 years in three university-based AD centers. Bivariate probit models estimated the effects of patient characteristics on home health and informal care utilization. A large majority of the patients (80.6%) received informal care with a smaller proportion (18.6%) receiving home health services. Home health services utilization increased from 9.9% at baseline to 34.5% in year 4. Among users, number of days that services were provided in three-month recall increased from 21.9 to 56 days over time. Home health services utilization was significantly associated with function, depressive symptoms, being female, and not living with a spouse. Informal care utilization was significantly associated with cognition, function, comorbidities, and living with a spouse or child. Home health and informal care utilization relate differently to patient characteristics. Utilization of home health care or informal care was not influenced by utilization of the other.
    Home Health Care Services Quarterly 02/2008; 27(1):1-20. DOI:10.1300/J027v27n01_01
  • [Show abstract] [Hide abstract]
    ABSTRACT: BackgroundDementia and Parkinsonism are two major neurodegenerative disorders. Accurate diagnosis can be difficult when patients have both syndromes because of a wide range of etiologies. ObjectivesTo improve clinical diagnosis, we propose a disease classification based on the pathological proteins which are involved in the neuropathological disease process. DesignFour neuropathological classes are proposed based on four major proteins, tau, Aβ, α-synuclein and TDP43: 1/ Tauopathy and amyloidopathy with possible Parkinsonism, 2/ Tauopathy with predominant Parkinsonism, 3/ Synucleinopathies with cognitive impairment/dementia and 4/ The TAR DNA binding protein 43 (TDP-43). This classification raises certain questions in clinical practice due to intriguing overlaps between clinical presentations despite the same pathological protein being involved. ConclusionThe development of molecular and pathological protein research in neurodegenerative disorders can help classify the clinical association of dementia and Parkinsonism and improve therapeutic strategies against proteins involved in the degenerative process. Key wordsParkinsonism-Alzheimer disease-frontotemporal lobar degeneration-lewy body dementia
    The Journal of Nutrition Health and Aging 01/2010; 14(1):37-44. DOI:10.1007/s12603-010-0007-z · 2.66 Impact Factor
Show more